The Effects and Safety of High Dose Vitamin D3 in Hemodialysis Patients

Overview

Journal Pharm Pract (Granada)

Date 2023 Apr 24

PMID 37090466

Authors

Adnane Guella

Abduelmula R Abduelkarem

Mohammed M Hassanein

Affiliations

Soon will be listed here.

Abstract

Background: Different studies have shown that hemodialysis patients require higher doses of Vitamin D3 (VD3) than the general population to achieve satisfactory replenishment. This study aims to assess the safety of such practice and its benefits on some of the parameters of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD).

Methods: A single-center clinical trial assessing the benefits of high dose VD3 in hemodialysis patients. The dose of VD3 (300,000 IU) was administered orally and monthly from April to December 2020 (9 months) at the dialysis unit. The data analyzed were blood levels of calcium, phosphorus, alkaline phosphatase, 25(OH)D, 1,25(OH)2D and intact parathyroid hormone (iPTH) done every three months.

Results: We could recruit a cohort of 23 patients. Blood levels of 25(OH)D increased significantly in 82.6% of the patients to above 30 ng/ml. A similar effect was observed with 1, 25(OH)2D levels. iPTH levels decreased significantly when levels of 25(OH)D exceeded 30ng/ml at the end of the nine months. Vitamin D serum levels were typically measured immediately before the next monthly dose was administered. Blood levels of calcium, phosphorus, and alkaline phosphatase were stable during the study period. No events of hypercalcemia were reported, and no patient discontinued the monthly VD3 supplementation.

Conclusion: Monthly administration of a high dose of VD3 over a long period of nine months in hemodialysis patients was found to be safe and beneficial in VD3 replenishment. It also allowed a significant decrease in iPTH levels. Further studies are warranted to identify the therapeutic target level of 25(OH)D in hemodialysis patients, allowing beneficial effects on iPTH.

Citing Articles

Hemodialysis Patients May Benefit from Cholecalciferol Treatment Targeting High Level of 25(OH)D.

Tarasewicz A, Dabrowska M, Komorniczak M, Zakrzewska A, Biedunkiewicz B, Malgorzewicz S Medicina (Kaunas). 2024; 60(11).

PMID: 39597015 PMC: 11596388. DOI: 10.3390/medicina60111831.

The Efficacy and Safety of High-Dose Cholecalciferol Therapy in Hemodialysis Patients.

Tarasewicz A, Komorniczak M, Zakrzewska A, Biedunkiewicz B, Malgorzewicz S, Jankowska M Biomedicines. 2024; 12(2).

PMID: 38397979 PMC: 10886943. DOI: 10.3390/biomedicines12020377.

References

Vieth R . Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999; 69(5):842-56. DOI: 10.1093/ajcn/69.5.842. View

Pike J, Meyer M . Regulation of mouse Cyp24a1 expression via promoter-proximal and downstream-distal enhancers highlights new concepts of 1,25-dihydroxyvitamin D(3) action. Arch Biochem Biophys. 2011; 523(1):2-8. PMC: 3314719. DOI: 10.1016/j.abb.2011.12.003. View

Alvarez J, Law J, Coakley K, Zughaier S, Hao L, Shahid Salles K . High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2012; 96(3):672-9. PMC: 3417221. DOI: 10.3945/ajcn.112.040642. View

Lu R, Zhu S, Tang F, Zhu X, Fan Z, Wang G . Effects of vitamin D or its analogues on the mortality of patients with chronic kidney disease: an updated systematic review and meta-analysis. Eur J Clin Nutr. 2017; 71(6):683-693. DOI: 10.1038/ejcn.2017.59. View

Massart A, Debelle F, Racape J, Gervy C, Husson C, Dhaene M . Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial. Am J Kidney Dis. 2014; 64(5):696-705. DOI: 10.1053/j.ajkd.2014.04.020. View

Friedl C, Zitt E . Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Int J Nephrol Renovasc Dis. 2017; 10:109-122. PMC: 5436758. DOI: 10.2147/IJNRD.S97637. View

Ennis J, Worcester E, Coe F, Sprague S . Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol. 2015; 29(1):63-70. DOI: 10.1007/s40620-015-0186-0. View

Levin A, Bakris G, Molitch M, Smulders M, Tian J, Williams L . Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2006; 71(1):31-8. DOI: 10.1038/sj.ki.5002009. View

Zehnder D, Bland R, Chana R, Wheeler D, Howie A, Williams M . Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol. 2002; 13(3):621-629. DOI: 10.1681/ASN.V133621. View

10.

Jean G, Souberbielle J, Chazot C . Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant. 2009; 24(12):3799-805. DOI: 10.1093/ndt/gfp370. View

11.

Kim S, Choi H, Lee J, Kim D, Oh Y, Kim Y . Prevalence of vitamin D deficiency and effects of supplementation with cholecalciferol in patients with chronic kidney disease. J Ren Nutr. 2013; 24(1):20-5. DOI: 10.1053/j.jrn.2013.07.003. View

12.

Mann M, Hobbs A, Hemmelgarn B, Roberts D, Ahmed S, Rabi D . Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis. Clin Kidney J. 2015; 8(1):41-8. PMC: 4310425. DOI: 10.1093/ckj/sfu122. View

13.

Dusso A, Rapp N, Slatopolsky E . Extra-renal production of calcitriol in chronic renal failure. Kidney Int. 1988; 34(3):368-75. DOI: 10.1038/ki.1988.190. View

14.

Tokmak F, Quack I, Schieren G, Sellin L, Rattensperger D, Holland-Letz T . High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant. 2008; 23(12):4016-20. DOI: 10.1093/ndt/gfn367. View

15.

Nigwekar S, Bhan I, Thadhani R . Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis. 2012; 60(1):139-56. DOI: 10.1053/j.ajkd.2011.12.035. View

16.

Wasse H, Huang R, Long Q, Singapuri S, Raggi P, Tangpricha V . Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis. Am J Clin Nutr. 2012; 95(2):522-8. PMC: 3260077. DOI: 10.3945/ajcn.111.025502. View

17.

Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O . 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation. 2005; 111(13):1666-71. DOI: 10.1161/01.CIR.0000160353.27927.70. View

18.

Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P . Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2008; 75(1):88-95. DOI: 10.1038/ki.2008.501. View

19.

Cupisti A, Vigo V, Baronti M, DAlessandro C, Ghiadoni L, Egidi M . Vitamin D status and cholecalciferol supplementation in chronic kidney disease patients: an Italian cohort report. Int J Nephrol Renovasc Dis. 2015; 8:151-7. PMC: 4657801. DOI: 10.2147/IJNRD.S90968. View

20.

Kalantar-Zadeh K, Kovesdy C . Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4(9):1529-39. DOI: 10.2215/CJN.02140309. View